At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 38 enrolled
Drug / intervention
TRC105 and Bevacizumabdrug
Likely dose
TRC105 and Bevacizumab 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating TRC105 and Bevacizumab for Adult Solid Tumor. Completed, enrolled 38 participants across 4 sites.
Detailed Summary
The purpose of the study is to evaluate safety and tolerability and determine a recommended Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced solid tumors for which bevacizumab is indicated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Solid Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionSep 2012
Study CompletionDec 2013
TodayJul 2026
First PostedApr 11, 2011
Enrollment StartApr 1, 2011
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.2 years ago
Interventions
TRC105 and Bevacizumabdrug
Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.